Brief: PharmAbcine Receives IND Approval From The Korean MFDS For Phase I Clinical Trial Of Its Novel TIE2 Agonistic Antibody In nAMD
23/05/2023 13:10
May 23 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE RECEIVES IND APPROVAL FROM THE KOREAN MFDS FOR
PHASE
I CLINICAL TRIAL OF ITS NOVEL TIE2 AGONISTIC ANTIBODY IN NAMD
Source text for Eikon: ID:nPn8wDNW3a
Further company coverage: 208340.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration